A randomized controlled double-blind trial of everolimus for improvingsocial abilities in pten germline mutations

Active Grant Awarded

Award ID
R01FD008531
Recipient
Awarding agency
Obligated
$647,968

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 4% complete
Funding agency
Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
Place of performance
Palo Alto, CA 94305, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Food and Drug Administration awarded The Leland Stanford Junior University $647,968 on September 23, 2026, under Grant R01FD008531, with the Office of Medical Products and Tobacco listed as an alternate agency name. The award falls under the Food and Drug Administration Research program (CFDA 93.103) and funds a 6-month, randomized, double-blind, placebo-controlled multi-site trial evaluating the efficacy and safety of everolimus for improving social abilities in people with PTEN germline mutations. The proposal names Stanford University, Cleveland Clinic, and Boston Children's Hospital as trial sites. The project rests on the premise that no drug treatments currently address the social or cognitive manifestations of PTEN hamartoma tumor syndrome, and on a prior pilot trial by the same group that reported improved social communication. Obligated funding is $647,968. The period of performance runs from the award date through June 30, 2030, and work is performed in Palo Alto, California 94305. The assistance type is Grant.

Description

Abstract
Germline heterozygous phosphatase and tensin homolog (PTEN) gene mutations, which fall under PTEN hamartoma tumor syndrome (PHTS), are rare with a rate of ~1 in 200,000 people. PHTS is associated with severe medical symptoms such as neurological and psychiatric conditions, including macrocephaly, intellectual disability, and autism symptomatology. Social deficits and other autistic symptomatology are particularly common in PHTS (>50%), with a rate of autism spectrum disorder at ~25%, such that PTEN germline mutations are considered pathogenic variants and a 'syndromic' form of autism. While the most prominent medical issues are managed by surveillance and early detection, there are currently no drug treatments for any of the social or cognitive manifestations of this neurogenetic disorder. This lack of efficacious treatment options causes significant burden, stress, and costs for individuals and their families. Thus, there is a critical need for safe and effective drug treatments that can target the core mechanisms of PHTS and benefit the associated social and cognitive deficits to improve quality of life. Everolimus is a particularly compelling treatment for targeting the symptoms of PHTS because PTEN is a dual specificity phosphatase that inhibits mammalian targets of rapamycin (MTOR) and everolimus is a form of rapamycin such that IT can directly target this MTOR pathophysiology. These areas of investigation for PHTS are also supported by a recent multicenter trial of everolimus conducted by our group that showed improvement of social communication during a randomized controlled pilot trial. In the current study, we propose a 6-month randomized, double-blind, placebo-controlled multi-site trial (stanford university, cleveland clinic (CC), and boston children's hospital (BCH)) to evaluate the efficacy and safety of everolimus in 60 individuals with PHTS and social deficits (age range 5-45 years). All participants in the controlled phase will also be invited to join a 6-month open-label trial after completion to aid in recruitment and retention and assess longer-term safety and impact on efficacy endpoints. Overall, the primary goals of our investigation are to directly target the pathophysiology of PHTS with everolimus and investigate whether IT can improve social communication abilities and other neurocognitive functioning to benefit quality of life. We will also explore potential biomarkers from eye tracking, EEG, and blood-based proteins for PTEN-associated molecules. If successful, our findings will help support approval for a new indication and changes in labeling for everolimus in treating social deficits of PHTS.

Quick answers

Who received award R01FD008531?

R01FD008531 was awarded to The Leland Stanford Junior University by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award R01FD008531 worth?

$647,968 has been obligated on R01FD008531.

Which agency awarded R01FD008531?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008531, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award